Here's What Vaccine CEOs Have to Say About the Omicron Variant

Here's What Vaccine CEOs Have to Say About the Omicron Variant
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

In that vein, in the days that followed the discovery of the potentially vaccine-evading omicron variant of SARS-CoV-2, the chief executives of Moderna (NASDAQ: MRNA), Pfizer (NYSE: PFE), and BioNTech (NASDAQ: BNTX) weighed in on the pandemic's latest complication. Stéphane Bancel, CEO of Moderna, rattled markets when he told the Financial Times on Nov. 29 that "I think it's going to be a material drop," referring to the efficacy of his company's jab against the omicron variant. In particular, he worried that Moderna's shot wouldn't perform as well as it had against the delta variant.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting